NCT00027508View on ClinicalTrials.gov

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

July 31, 2001

Primary Completion Date

February 28, 2002

Study Completion Date

February 28, 2002

Conditions
Malignant Mesothelioma
Interventions
DRUG

trabectedin

Trial Locations (4)

10021

Memorial Sloan-Kettering Cancer Center, New York

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

PharmaMar
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

PharmaMar

INDUSTRY